Sentinel node biopsy (SNB) significantly reduced the risk of death from melanoma in patients with feline melanoma. In a systematic review and meta-analysis of 13 studies with more than 40,000 participants, the pooled hazard ratio (HR) in the main adjusted analysis was 0.86 (95% CI 0.81–0.92; p<0.0001) with low heterogeneity (I²=16%). The risk of dying from melanoma was reduced by 14% and the risk of recurrence by 29%. Analysis of 5-year melanoma-specific survival in 5 studies with 27,540 participants showed a pooled HR of 0.84 (95% CI 0.78–0.90; p<0.0001) with I²=15%. Results were stable across sensitivity analyses. These findings support SNB as a procedure with therapeutic value beyond staging.[1]